Onco Actu du 3 septembre 2015

	3.1 Tabac
Switching From Conventional to Electronic Cigarettes Reduced Toxicant Exposure, Even for Dual Users [AACR] The researchers measured carbon monoxide in participants’ breath one week before switching to the e-cigarettes, the day of switching, and once a week for the next four weeks. They also analyzed urine samples provided by participants the day of switching and four weeks after switching, looking for a biomarker of exposure to acrolein.
	4.2 Dép., diag. & prono. - Génome
Genetic landscape can impact treatment for children with rare, aggressive cancer [University of Michigan] 25 percent of patients went on to receive a study recommended novel therapy, which resulted in 10 percent of patients achieving a partial or complete remission lasting six month or longer.
	5. Traitements
Recognising and reducing the risk of chemotherapy extravasation [Cancer World] When chemotherapy drugs leak from the veins it can cause serious injury to the patient, greatly heighten their fears of undergoing future treatment cycles, and undermine their trust in their medical team. Knowing how to assess and reduce the risks, and what to do when things go wrong, is essential.
	5.12 Immunothérapies
Ziopharm tests new approach to engineering CAR-Ts for solid tumors [FierceBiotech] "An important derivative of this study is that scientists can now tweak, or modulate, the affinity of a CAR T cell to meet the needs of a given tumor."
Some leukemia patients see durable results from Novartis therapy [Reuters] The treatment is made by taking immune system soldiers called T cells from the body, genetically modifying them to have cancer-spotting abilities of antibodies, and then infusing the altered cells back into the patient. The first patient to receive the therapy is cancer-free after five years and another of the first three enrolled patients also remains in remission, the university said on Wednesday.
	5.2.1 Pharma - Partenariats
After partnering with Big Pharmas, Incyte bags its own PD-1 drug in $795M deal [FierceBiotech] Incyte has inked a global deal with China's Jiangsu Hengrui Medicine for an anti-PD-1 drug dubbed SHR-1210. In exchange for $25 million upfront and a heavily back ended $770 million package of milestones.
	5.3 Traitements - FDA, EMA,...
U.S. Food and Drug Administration Accepts Supplemental Biologics License Appliction for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients [BMS] This sBLA seeks to expand the current indication for Opdivo in patients with previously treated squamous (SQ) NSCLC. The projected FDA action date is January 2, 2016.
	5.3.4 Traitements - AMM (FDA, EMA)
FDA Approves Pediatric Indication for EMEND® (aprepitant) Capsules in Combination with Other Antiemetic Agents [Merck] With this approval, EMEND is the first and only NK1 receptor antagonist to be approved for the prevention of acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV) in patients 12 to 17 years of age and patients less than 12 years who weigh at least 30 kg receiving HEC or MEC.
FDA approves new drug treatment for nausea and vomiting from chemotherapy [FDA] Varubi (rolapitant) is a substance P/neurokinin-1 (NK-1) receptor antagonist. Activation of NK-1 receptors plays a central role in nausea and vomiting induced by certain cancer chemotherapies, particularly in the delayed phase. Varubi is provided to patients in tablet form.
	6. Lutte contre les cancers
Two years on for our pioneering TRACERx lung cancer study [Cancer Research UK] The study has now recruited nearly 200 patients – just under a quarter of the overall target. And alongside all the original plans for DNA analysis (which we wrote about when the trial launched) Swanton’s team have opened up several new fronts.
HHS announces proposal to update rules governing research on study participants [HHS] This proposes to modernize the current regulations by enhancing the ability of individuals to make informed decisions about participating in research, while reducing unnecessary burdens by streamlining the regulatory requirements for low-risk research.
	6.1 Observation
Prophylactic Surgery Nearly Doubles in Men with Breast Cancer [ACS] “The increase in the rate of this costly, serious procedure with no evidence of survival benefit comes, paradoxically, at a time of greater emphasis on quality and value in cancer care,” said Dr. Jemal.
Study supports watch-and-wait approach for many prostate cancers [Reuters] The researchers followed 1,268 men, mostly in their 60s, diagnosed with low-risk or very low-risk prostate cancer in the 2000s. As part of active surveillance, the men had twice-yearly rectal exams and blood tests for prostate specific antigen (PSA) and annual prostate biopsies.
	6.11 Patients
Contributing Op-Ed Writer: Was It Cancer? Getting the Diagnosis [NY Times] For me, one of the most excruciating parts of going through something like cancer is the need to talk to strangers about your internal organs.
	6.7 DMP, Big Data & applis
Topol Calls on Healthcare Industry to “Emancipate” Patient Data [Xconomy] For example, Topol said patient data should be stored in a “private cloud.” Under a private cloud model, the pool of Web servers is distinct and secure, and only accessible by a single organization, which provides greater control and privacy. “If you don’t have your own data in a private cloud, you’re just waiting to get hacked,” he said.